Frederick R. Aronson

1.6k total citations
28 papers, 1.2k citations indexed

About

Frederick R. Aronson is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Frederick R. Aronson has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 14 papers in Immunology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Frederick R. Aronson's work include Cancer Immunotherapy and Biomarkers (11 papers), Immune Cell Function and Interaction (7 papers) and Immunotherapy and Immune Responses (7 papers). Frederick R. Aronson is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immune Cell Function and Interaction (7 papers) and Immunotherapy and Immune Responses (7 papers). Frederick R. Aronson collaborates with scholars based in United States, Malaysia and Switzerland. Frederick R. Aronson's co-authors include Kim Margolin, Mario Sznol, Michael B. Atkins, James H. Doroshow, Robert P. Numerof, Janice P. Dutcher, Geoffrey R. Weiss, J W Mier, Reta S. Gibbons and Olivia M. Martinez and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Frederick R. Aronson

28 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Frederick R. Aronson United States	21	692	596	234	207	128	28	1.2k
Raymond A. Kempf United States	22	935 1.4×	899 1.5×	467 2.0×	246 1.2×	122 1.0×	48	1.7k
Jens Schreiner Germany	15	535 0.8×	649 1.1×	204 0.9×	153 0.7×	146 1.1×	22	1.2k
S A Rosenberg United States	8	336 0.5×	264 0.4×	223 1.0×	161 0.8×	95 0.7×	10	946
Yoshikata Misaki Japan	19	809 1.2×	247 0.4×	221 0.9×	112 0.5×	71 0.6×	38	1.3k
Witold B. Rybka United States	21	797 1.2×	676 1.1×	254 1.1×	86 0.4×	320 2.5×	79	1.7k
Vittore Cereda Italy	18	733 1.1×	859 1.4×	352 1.5×	305 1.5×	104 0.8×	30	1.3k
Ricardo Giscombe Sweden	23	1.1k 1.5×	415 0.7×	202 0.9×	301 1.5×	130 1.0×	41	1.7k
JL Ferrara United States	8	1.3k 1.9×	282 0.5×	200 0.9×	108 0.5×	102 0.8×	10	2.0k
Nanette McAtee United States	12	206 0.3×	377 0.6×	241 1.0×	169 0.8×	100 0.8×	16	1.0k
V von Fliedner Switzerland	22	1.2k 1.7×	881 1.5×	411 1.8×	115 0.6×	108 0.8×	54	2.1k

Countries citing papers authored by Frederick R. Aronson

Since Specialization

Citations

This map shows the geographic impact of Frederick R. Aronson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick R. Aronson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick R. Aronson more than expected).

Fields of papers citing papers by Frederick R. Aronson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frederick R. Aronson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick R. Aronson. The network helps show where Frederick R. Aronson may publish in the future.

Co-authorship network of co-authors of Frederick R. Aronson

This figure shows the co-authorship network connecting the top 25 collaborators of Frederick R. Aronson. A scholar is included among the top collaborators of Frederick R. Aronson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Frederick R. Aronson. Frederick R. Aronson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ready, Neal, et al.. (2005). A Low Rate of Central Nervous System Progression in a Phase II Trial of Outpatient Chemobiologic Therapy With Cisplatin, Temozolomide, Interleukin-2, and Interferon Alfa 2-B for Metastatic Malignant Melanoma. American Journal of Clinical Oncology. 28(5). 479–484. 5 indexed citations

Wolf, J. Stuart, Frederick R. Aronson, Eric J. Small, & Peter R. Carroll. (1994). Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. Journal of Surgical Oncology. 55(1). 7–13. 30 indexed citations

Margolin, Kim, Frederick R. Aronson, Mario Sznol, et al.. (1994). Phase II Studies of Recombinant Human Interleukin-4 in Advanced Renal Cancer and Malignant Melanoma. Journal of Immunotherapy. 15(2). 147–153. 51 indexed citations

Hawkins, Michael, Michael B. Atkins, Janice P. Dutcher, et al.. (1994). A Phase II Clinical Trial of Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Colorectal Carcinoma. Journal of Immunotherapy. 15(1). 74–78. 21 indexed citations

Sparano, Joseph A., Richard I. Fisher, Geoffrey R. Weiss, et al.. (1994). Phase II Trials of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Advanced Breast Carcinoma and Carcinoma of the Lung, Ovary, and Pancreas and Other Tumors. Journal of Immunotherapy. 16(3). 216–223. 24 indexed citations

Sosman, Jeffrey A., Geoffrey R. Weiss, Kim Margolin, et al.. (1993). Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects.. Journal of Clinical Oncology. 11(8). 1496–1505. 31 indexed citations

Weiss, Geoffrey R., Kim Margolin, Frederick R. Aronson, et al.. (1992). A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.. Journal of Clinical Oncology. 10(2). 275–281. 104 indexed citations

Valone, Frank H., David R. Gandara, Albert Deisseroth, et al.. (1991). Interleukin-2, Cisplatin, and 5-Fluorouracil for Patients with Non-Small Cell Lung and Head/Neck Carcinomas. Journal of Immunotherapy. 10(3). 207–213. 25 indexed citations

Saxon, Richard R., M H Bar, Paul D. Blanc, et al.. (1991). Pathogenesis of pulmonary edema during interleukin-2 therapy: correlation of chest radiographic and clinical findings in 54 patients.. American Journal of Roentgenology. 156(2). 281–285. 27 indexed citations

10.

Margolin, Kim, Frederick R. Aronson, Mario Sznol, et al.. (1991). Phase II Trial of High-Dose Interleukin-2 and Lymphokine-Activated Killer Cells in Hodgkin??s Disease and Non-Hodgkin??s Lymphom. Journal of Immunotherapy. 10(3). 214–220. 21 indexed citations

11.

Aronson, Frederick R., et al.. (1991). Life-Threatening Bullous Skin Eruptions During Interleukin-2 Therapy. JNCI Journal of the National Cancer Institute. 83(1). 56–57. 11 indexed citations

12.

Benz, Christopher C., et al.. (1991). Gossypol effects on endothelial cells and tumor blood flow. Life Sciences. 49(12). PL67–PL72. 13 indexed citations

13.

Wilkinson, Mary & Frederick R. Aronson. (1991). Use of Biological Response Modifiers for Management of Renal Cell Carcinoma. Urologia Internationalis. 46(3). 304–308. 3 indexed citations

14.

Parkinson, David, Peter H. Wiernik, Anthony A. Rayner, et al.. (1990). Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.. Journal of Clinical Oncology. 8(10). 1650–1656. 163 indexed citations

15.

Gaynor, Ellen R., Geoffrey R. Weiss, Kim Margolin, et al.. (1990). Phase I Study of High-Dose Continuous-Infusion Recombinant Interleukin-2 and Autologous Lymphokine-Activated Killer Cells in Patients With Metastatic or Unresectable Malignant Melanoma and Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute. 82(17). 1397–1402. 34 indexed citations

16.

Bar, M H, Mario Sznol, Michael B. Atkins, et al.. (1990). Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.. Journal of Clinical Oncology. 8(7). 1138–1147. 66 indexed citations

17.

Aronson, Frederick R., et al.. (1988). IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury.. The Journal of Immunology. 141(1). 158–163. 85 indexed citations

18.

Mier, James W., Frederick R. Aronson, Robert P. Numerof, Gloria Vachino, & Michael B. Atkins. (1988). Toxicity of Immunotherapy with Interleukin-2 and Lymphokine-Activated Killer Cells. Pathology and Immunopathology Research. 7(6). 459–476. 41 indexed citations

19.

Aronson, Frederick R., Roy A. Dempsey, Mark Allegretta, et al.. (1987). Malignant granular lymphoproliferation after Epstein‐Barr virus infection: Partial immunologic reconstitution with interleukin‐2. American Journal of Hematology. 25(4). 427–439. 17 indexed citations

20.

Wolfe, Harold R., et al.. (1960). The Secondary Response of Chickens Given a Primary Inoculation of Bovine Serum Albumin at Different Ages. International Archives of Allergy and Immunology. 17(1-2). 106–115. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact